Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Cash from Financing Activities of $1.5 million for Q1 2026, up 2820.64% year-over-year from $50354.0 in Q1 2025, and down 99.41% quarter-over-quarter from $248.8 million in Q4 2025.
Capricor Therapeutics (CAPR) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 2820.64% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $250.3 million (up 66.29% YoY), while the FY2025 annual figure was $248.9 million, up 62.92% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $1.5 million, down from $248.8 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $248.8 million in Q4 2025, with the low at $3895.0 in Q1 2023.
- The 5-year median for Cash from Financing Activities is $1.9 million (2022), against an average of $25.5 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 58699.59% in 2024, then sank 99.99% in 2025.
- Capricor Therapeutics' Cash from Financing Activities stood at $2.9 million in 2022, then soared by 685.45% to $23.2 million in 2023, then surged by 250.01% to $81.1 million in 2024, then surged by 206.85% to $248.8 million in 2025, then sank by 99.41% to $1.5 million in 2026.
- Business Quant data shows CAPR's Cash from Financing Activities at $1.5 million in Q1 2026, $248.8 million in Q4 2025, and $6950.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 248.82 Mn |
| Dec 31, 2025 | 248.82 Mn |
| Sep 30, 2025 | 6,950.00 |
| Sep 30, 2025 | 6,950.00 |
| Jun 30, 2025 | 19,580.00 |
| Jun 30, 2025 | 19,580.00 |
| Mar 31, 2025 | 50,354.00 |
| Mar 31, 2025 | 50,354.00 |
| Dec 31, 2024 | 81.09 Mn |
| Dec 31, 2024 | 81.09 Mn |
| Sep 30, 2024 | 67.33 Mn |
| Sep 30, 2024 | 67.33 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Dec 31, 2023 | 23.17 Mn |
| Dec 31, 2023 | 23.17 Mn |